TWI492747B - 壓縮製劑 - Google Patents

壓縮製劑 Download PDF

Info

Publication number
TWI492747B
TWI492747B TW096122976A TW96122976A TWI492747B TW I492747 B TWI492747 B TW I492747B TW 096122976 A TW096122976 A TW 096122976A TW 96122976 A TW96122976 A TW 96122976A TW I492747 B TWI492747 B TW I492747B
Authority
TW
Taiwan
Prior art keywords
dissolution
composition
satan
ingot
tablet
Prior art date
Application number
TW096122976A
Other languages
English (en)
Chinese (zh)
Other versions
TW200815000A (en
Inventor
Shuichi Yada
Susumu Hasegawa
Mitsuhide Tanimoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38845498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI492747(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of TW200815000A publication Critical patent/TW200815000A/zh
Application granted granted Critical
Publication of TWI492747B publication Critical patent/TWI492747B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096122976A 2006-06-27 2007-06-26 壓縮製劑 TWI492747B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006176146 2006-06-27

Publications (2)

Publication Number Publication Date
TW200815000A TW200815000A (en) 2008-04-01
TWI492747B true TWI492747B (zh) 2015-07-21

Family

ID=38845498

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096122976A TWI492747B (zh) 2006-06-27 2007-06-26 壓縮製劑

Country Status (9)

Country Link
US (1) US20100237530A1 (https=)
EP (1) EP2033643A4 (https=)
JP (2) JP5769362B2 (https=)
KR (1) KR101628028B1 (https=)
CN (1) CN101478966B (https=)
BR (1) BRPI0713371A2 (https=)
CA (1) CA2656181C (https=)
TW (1) TWI492747B (https=)
WO (1) WO2008001734A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2510866T3 (es) 2008-03-13 2014-10-21 Daiichi Sankyo Company, Limited Mejora de la solubilidad de una preparación que contiene olmesartán medoxomilo
JP2011136908A (ja) * 2009-12-25 2011-07-14 Kyowa Yakuhin Kogyo Kk アンギオテンシンｉｉ受容体拮抗剤を含む固形製剤および固形製剤におけるアンギオテンシンｉｉ受容体拮抗剤の保存安定性向上方法
CN102119930B (zh) * 2010-07-13 2013-01-30 福建天泉药业股份有限公司 一种奥美沙坦酯片及制备方法
EP2425859A1 (en) 2010-08-08 2012-03-07 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Olmesartan formulations
CN102028663B (zh) * 2010-12-14 2011-11-30 北京万生药业有限责任公司 一种稳定的奥美沙坦酯固体制剂
IN2014MN01919A (https=) * 2012-03-30 2015-07-10 Dae Woong Pharma
CN105663070A (zh) * 2014-11-21 2016-06-15 深圳信立泰药业股份有限公司 一种含有奥美沙坦酯的药物组合物及其制备方法
CN105640913B (zh) * 2016-01-22 2018-11-02 山东省医学科学院药物研究所 一种奥美沙坦酯片及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
WO2005042022A2 (en) * 2003-10-29 2005-05-12 Pfizer Limited Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0282519A (ja) 1988-09-19 1990-03-23 Sanyo Electric Co Ltd 固相エピタキシャル成長方法
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
WO2000003735A1 (fr) * 1998-07-15 2000-01-27 Asahi Kasei Kogyo Kabushiki Kaisha Excipient
JP3796562B2 (ja) * 1999-05-26 2006-07-12 ライオン株式会社 多層錠、多層錠の製造方法及び多層錠の剥離抑制方法
AU6786001A (en) * 2000-07-05 2002-01-14 Asahi Chemical Ind Cellulose powder
JP2002167327A (ja) * 2000-09-22 2002-06-11 Takeda Chem Ind Ltd 固形製剤
US20040132731A1 (en) * 2002-06-26 2004-07-08 Fox David Nathan Abraham Novel combination
MXPA05008142A (es) * 2003-01-31 2005-09-30 Sankyo Co Medicamento para la profilaxis y el tratamiento de arteriosclerosis e hipertension.
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
US8647668B2 (en) * 2003-10-15 2014-02-11 Fuji Chemical Industry Co., Ltd. Tablet quickly disintegrating in oral cavity
MXPA06004639A (es) * 2003-10-31 2006-06-27 Takeda Pharmaceutical Preparacion solida que comprende sensibilizador de insulina, secretagogo de insulina y ester de acidos grasos de polioxietileno sorbitano.
KR20090102883A (ko) * 2004-09-02 2009-09-30 테바 파마슈티컬 인더스트리즈 리미티드 올메살탄 메독소밀의 정제
CA2613417C (en) * 2005-06-27 2011-11-29 Daiichi Sankyo Company, Limited Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
JP5110697B2 (ja) * 2005-06-27 2012-12-26 第一三共株式会社 固形製剤
EP1891952B1 (en) * 2006-05-04 2011-10-05 LEK Pharmaceuticals d.d. Pharmaceutical composition of olmesartan medoxomil

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
WO2005042022A2 (en) * 2003-10-29 2005-05-12 Pfizer Limited Combination of an activator of solubleguanylate cyclase and an angiotensin ii receptor antagonist

Also Published As

Publication number Publication date
KR20090021184A (ko) 2009-02-27
CA2656181C (en) 2011-09-06
US20100237530A1 (en) 2010-09-23
JPWO2008001734A1 (ja) 2009-11-26
KR101628028B1 (ko) 2016-06-08
JP2014024874A (ja) 2014-02-06
TW200815000A (en) 2008-04-01
CN101478966A (zh) 2009-07-08
JP5769362B2 (ja) 2015-08-26
EP2033643A1 (en) 2009-03-11
CA2656181A1 (en) 2008-01-03
WO2008001734A1 (en) 2008-01-03
EP2033643A4 (en) 2013-01-02
CN101478966B (zh) 2013-08-21
BRPI0713371A2 (pt) 2012-03-13

Similar Documents

Publication Publication Date Title
TWI492747B (zh) 壓縮製劑
TWI388345B (zh) 用於高血壓之預防或治療之包含血管緊張素ⅱ受體拮抗劑及鈣通道阻斷劑之固體劑型
EP1814527B2 (en) Bilayer tablet comprising telmisartan and amlodipine
TWI482641B (zh) 含有低取代度羥丙基纖維素之醫藥組成物
TWI428151B (zh) 含有甘露醇或乳糖之固形製劑
TWI399223B (zh) 奧美沙坦酯及氨氯地平之固體劑型
TWI433671B (zh) 含奧美沙坦酯之製劑之溶出性之改善
CN101247832A (zh) 含有血管紧张素ⅱ受体拮抗剂和钙通道阻断剂的药物制剂
CN106232144B (zh) 固体分散体
US20100062070A1 (en) Pulverzed crystals of olmesartan medoxomil
TW200831138A (en) Pharmaceutical composition of improved storage stability
KR20090130325A (ko) 약학 부형제 복합체
KR20150068993A (ko) 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제
EP2586424B1 (en) Pharmaceutical combinations comprising an angiotensin II receptor antagonist, hydrochlorothiazide and a disintegrant.
WO2005089720A1 (en) Valsartan tablets and the process for the preparation thereof
CN112716951A (zh) 包含氨氯地平和氯沙坦的固体药物组合物
HK1127286A (en) Compressed preparation
JP2017008018A (ja) 溶出改善されたオルメサルタンメドキソミル錠
MURALI Prof. Dr. K. Senthilkumaran, M. Pharm, Ph. D.